Physician profile
Daniel Sorial
NPI 1720781719
$3,480.88
in general payments reported to CMS, 2019-2025
24 companies · $1,913 in 2025
The $1,913 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $707 · 2024: $861 · 2025: $1,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,480.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $928.94 | 2023-2025 | Qulipta, Ubrelvy |
| Ucb, INC. | $639.14 | 2023-2025 | Zilbrysq, Briviact, Rystiggo |
| Emd Serono, INC. | $362.05 | 2024-2025 | |
| Eisai INC. | $221.32 | 2024-2025 | |
| Mdd US Operations, LLC | $186.90 | 2023-2025 | Gocovri, Apokyn |
| Neurocrine Biosciences, INC. | $163.82 | 2025 | |
| Novartis Pharmaceuticals Corporation | $150.70 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $120.38 | 2023 | |
| Biogen, INC. | $72.85 | 2024-2025 | Vumerity |
| Lundbeck LLC | $70.44 | 2024-2025 | Vyepti |
| Jazz Pharmaceuticals INC. | $69.74 | 2023-2024 | Epidiolex |
| Sk Life Science, INC. | $67.63 | 2025 | Xcopri |
| Takeda Pharmaceuticals U.S.A., INC. | $67.29 | 2024-2025 | Hyqvia |
| Pfizer INC. | $65.44 | 2024 | |
| Genentech USA, INC. | $55.08 | 2025 | Ocrevus, Ocrevus Zunovo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $48.78 | 2025 | Nuplazid |
| Genzyme Corporation | $45.12 | 2024 | |
| Lilly USA, LLC | $35.11 | 2025 | Kisunla, Amyvid |
| Merz Pharmaceuticals, LLC | $22.64 | 2025 | Inbrija, Xeomin, Ampyra |
| Argenx US, INC. | $21.25 | 2024 | Vyvgart, Vyvgart Hytrulo |
| Neurelis, INC. | $18.95 | 2025 | Valtoco |
| Axsome Therapeutics, INC. | $17.15 | 2024 | Sunosi |
| Kyowa Kirin, INC. | $16.16 | 2024 | Nourianz |
| Astrazeneca Pharmaceuticals Lp | $14.00 | 2025 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sorial listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.